PMC4898290_01
84-year-old male with prostate cancer. After rising PSA, nuclear medicine bone scan shows diffuse disease metastatic to the skeleton. The left image shows the anterior projection, and the right image shows the posterior projection.
gr1.jpg
PMC4898290_01_gr1.jpg
fig1
Due to subsequent biochemical failure (rising PSA) approximately eight years later, he presented for a nuclear medicine bone scan, which showed diffuse osteoblastic metastatic skeletal disease (Fig. 1).
84-year-old male with prostate cancer. Nuclear medicine bone scan approximately six months after continuous hormone deprivation therapy demonstrates a mixed pattern of improvement and progression of skeletal metastases. Improvement of skeletal metastases is best appreciated in the upper thoracic region. The left image shows the anterior projection, and the right image shows the posterior projection.
gr2.jpg
PMC4898290_01_gr2.jpg
fig2
The patient was started on luteinizing hormone-releasing hormone (LHRH) agonist and antiandrogen therapy at that time and returned for a followup bone scan approximately six months after initiation of continuous hormone deprivation therapy (Fig. 2).